Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the St. Vincent's Hospital Melbourne...

Related Keywords

Australia , California , United States , Melbourne , Victoria , Sydney , New South Wales , San Francisco , David Stamler , Vincent Hospital Melbourne Human Research Ethics Committee , National Institute Of Health , European Commission , Alterity Therapeutics , Nasdaq , Parkinsonian Disorder , Multiple System Atrophy , Chief Executive Officer , System Atrophy , Neurological Disorders , Multiple System Atrophy Fact ,